Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen and SUBA-Itraconazole in Platinum Resistant Ovarian Cancer
NCT05156892Phase 1Active, not recruiting
- Start
- Sep 2022
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SUBA itraconazole and tamoxifen in ovarian cancer. Primary endpoint: Recommended Phase 2 Dose at 1 year. Started Sep 2022; status: active, not recruiting.
02
Drugs
SUBA itraconazoletamoxifen
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05156892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156892.